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Summary Using a cell line derived from the VM spontaneous murine astrocytoma, a reliable in vitro-in vivo
model of human malignant glioma has been developed. In this paper we examine the effects of cytotoxic drugs
with known activity against other animal brain tumour models and human disease on the in vivo VM model.
The drugs BCNU, CCNU and vincristine produced significant volume reduction in tumours growing at a
subcutaneous location in syngeneic animals. Procarbazine was ineffective. Similarly, BCNU, CCNU and
vincristine produced small but statistically significant increases in survival of VM mice bearing the intra-
cerebral tumour, but procarbazine was again ineffective. The modest, but significant, response of the VM
model to the nitrosoureas mimics the human situation more closely than previously described animal models.
A cell line VMDk 497-P(1), derived from the VM spon-
taneous murine astrocytoma (Fraser, 1980), has been used to
develop an in vitro-in vivo model of human glioma. The cell
line can be grown as monolayer cultures and as multicellular
tumour spheroids (Bradford et al., 1989a). It also produces
tumours at subcutaneous and intracranial sites when
inoculated into syngeneic VM mice. In a previous report
(Bradford et al., 1989b) we described the development of the
in vivo model and showed that cell line 497-P(1) provides the
basis for a reliable and reproducible model of glioma, which
fulfils many of the criteria required for experimental therapy.
In this paper we describe the response of subcutaneous and
intracranial tumours produced by VMDk 497-P(1) cells to
treatment with BCNU, CCNU, vincristine (VCR) and pro-
carbazine (PCB). These agents were chosen because their
activity against human malignant glioma (Green et al., 1983)
and other animal brain tumour models (Schold & Bigner,
1983) has been documented.
Materials and methods
Cell lines
The 497-P(I) cells are a derivative (Bradford et al., 1989a) of
a cell line, VMDk P497, the gift of Dr D. Bigner (Duke
University Medical Center, Durham, North Carolina, USA).
Cells were maintained in culture by methods previously des-
cribed by Pilkington et al. (1983). VM mice were bred at the
Institute of Neurology and were the descendents of six
breeding pairs supplied by Dr H. Fraser (ARC and MRC
Neuropathogenesis Unit, Edinburgh).
Drug toxicity
This was determined in non tumour-bearing animals. The
LD50 was determined for BCNU, CCNU, VCR and PCB
using the method described by Thompson (1947) and by
reference to published tables (Weil, 1952). Drugs were
administered by i.p. injection in a total volume of 0.01 ml g-'
body weight. For each drug four groups of four animals were
dosed at levels spaced by a geometric factor of two. The
mortality in each group was recorded at 30 days. In accord-
ance with the observations of others (Shapiro & Basler, 1979)
it was not possible to determine a reliable LD50 for PCB. The
dosage schedules for this drug were therefore based on
previous reports (Geran et al., 1974; Bradley et al., 1983;
Schold & Bigner, 1983). For BCNU, CCNU and VCR,
tumour-bearing animals were dosed with 0.5 of the calculated
LD5,.
Chemotherapy ofsubcutaneous tumours
On day 0 VM mice were inoculated subcutaneously with 106
497-P(l) cells harvested immediately beforehand from a near-
confluent monolayer culture. Bilateral inoculations were per-
formed in order to minimise the number of animals used to
achieve statistical significance (Warenius et al., 1980). On day
6, when subcutaneous nodules became measurable with
calipers, mice were randomly divided into groups of five. One
group served as a common control for the treatment groups.
Treatment was begun on day 10 when tumour growth had
become well established. Drugs were administered to groups
of mice in the following doses and schedules and on succes-
sive occasions: BCNU as either a single injection of
30 mg kg-' or five successive daily doses of 6 mg kg- ';
CCNU as either a single injection of 30 mg kg-' or five
successive daily doses of 6 mg kg-'; VCR as five successive
daily doses of 270 ,ug kg-'; PCB as five successive daily doses
of either 100, 200 or 300 mg kg-'. For experiments with PCB
in the above doses and acted as drug controls.
Subcutaneous tumours were measured on day 6, on each
day during the treatment period and thereafter two or three
times weekly. On each occasion the width, length and depth
of the tumour were recorded. Using these measurements, the
tumour mass was expressed as a volume by substituting in a
previously reported weight equation (Steel, 1977)
The number of individual tumours regressing to a tumour
volume less than the volume at the start of treatment was
determined and expressed as a fraction of the total number
of treated tumours. The ratio of the mean treated tumour to
the mean control tumour volume (T/C) on day 21 was
determined. Mean growth delay (GD) was measured by the
method described by Houghton and Houghton (1983) using
the equation:
GD = X(Tt-T0) _ (C,-C.)
n n
where Tt and C, are the days at which individual tumours
reached four times their volume from the day of treatment
(TO, CO) for treated and control tumours respectively and n is
the number of tumours per group.
Chemotherapy ofintracerebral tumours
VM mice were inoculated intracerebrally with 497-P(1) cells
in the manner previously described (Pilkington et al., 1985;
Bradford et al., 1989b). Twenty-four hours later mice were
randomly divided into control or treatment groups of 10
animals per group. Treatment was begun on day 6 following
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inoculation. All animals were weighed on the day of tumour
cell inoculation and on the days of drug administration.
Drugs were administered intraperitoneally in the doses and
schedules described for subcutaneous treatment above. For
humane reasons moribund animals were killed by cranio-
cervical dislocation.
The day of death was recorded for each mouse in control
and treatment groups. The median day of death of the
treated groups (7) was compared to the median day of death
of the untreated control groups (C) and the per cent in-
creased life-span (%ILS) determined thus:
ILS=(T/C)x 100%
ILS values from experiments which were performed on two
separate occasions were averaged to yield the mean increased
life-span. An ILS of 25% was considered as indicative of
activity (Geran et al., 1974). Survival times of treated and
control were compared using the Wilcoxon rank-sum test.
Results
Chemotherapy ofsubcutaneous tumours
In the course of these experiments 110 subcutaneous inocula-
tions were performed, resulting in 102 tumours (93%).
Control groups consisted of at least 10 tumours. The growth
curve of untreated tumours is Gompertzian in form and the
volume doubling time is approximately 1.4 days and 5.1 days
at small and large volumes respectively (Bradford et al.,
1989b). The complete results are shown in Table I.
BCNU Eight tumours were treated with a single dose of
30 mg kg-' BCNU on day 10 following inoculation. All eight
tumours regressed in size from the initial treatment volume.
Tumour regression was, however, transient and regrowth
occurred between 2 and 3 days after treatment (Figure 1).
there was a significant volume reduction of treated tumours
at day 21 with a TIC of 0.14. The mean growth delay to four
times the treatment volume was 7.6 days. BCNU given as
five successive daily doses of 6 mg kg-' also produced
tumour regression in nine out of nine tumours (Figure 1).
Again tumour regression was transient and regrowth in eight
of the nine tumours began before the end of the treatment
schedule. Three tumours initially regrew at a more rapid rate
than the pre-treatment growth rate. Both the TIC of 0.25 and
the GD of 6.7 were smaller than those seen when the same
dose of BCNU was given as a single injection.
CCNU Regression occurred in eight of nine and seven of 10
tumours treated with a single dose of 30 mg kg-' or five
consecutive doses of 6 mg kg-' CCNU respectively. All
tumours which regressed resumed growth within 2 or 3 days.
Both schedules of CCNU produced significant volume reduc-
tion at day 21 although this was less than that observed for
BCNU (Table I). There was a marked difference in GD
produced by the two schedules of CCNU. While a single
dose of 30 mg kg-' produced a GD of 6.3 days, the GD for
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Figure 1 The effect of BCNU on the growth of subcutaneous
implants of the 497-P(1) murine astrocytoma. a, the influence of a
single dose of BCNU (30 mgkg-') on the growth of individual
subcutaneous tumours. b, the effect of treatment with BCNU
(6 mg kg Ix 5) in daily divided doses on the growth of sub-
cutaneous tumours. The dashed line is the mean tumour volume
of the control group.
the multiple dose schedule was 3.1 days. This was the
shortest GD produced by any schedule involving the nit-
rosoureas.
VCR Five successive daily doses of 270 jig kg-' of VCR
produced marked variability in individual tumour response.
Only four of the nine treated tumours regressed to a volume
smaller than the initial treatment volume. The mean tumour
volume ofthe treated group at day 21 was less than halfthat of
the control group with a TIC of0.46. VCR produced a modest
GD of 2.5 days.
PCB PCB was intially administered as five consecutive doses
of 100 mg kg-'. This dose produced a small and transient
Table I Chemotherapy of497-P(1) subcutaneous tumours
Tumour Mean Ratio GD
Group regressionsa (V,IVjb PC (TIC) (days)
BCNU 30mgkg' x 1 8/8 171 ± 97/1233 ± 321 0.001 0.14 7.6
6mgkg' x 5 9/9 298± 164/1173± 196 0.001 0.25 6.7
CCNU 30mgkg' x 1 8/9 234± 133/1233 ± 321 0.001 0.19 6.3
6 mg kg- x 5 7/10 502 ± 219/1352 ± 582 0.004 0.37 3.1
PCB 100 mg kg-' x 5 2/8 952 ± 288/1352 ± 582 0.09 0.70 1.4 200mgkg'x 5 1/9 804±228/1173± 196 0.002 0.69 0.3
300 mg kg-] x 5 O/Iod 785 ± 189/1173 ± 196 0.002 0.67 0.7
VCR 270fg kg- x 5 4/9 620 ± 275/1352 ± 582 0.003 0.46 2.5
aNumber of tumour regression/total number of tumours treated. bMean treated tumour volume (mm3 ± s.d.)/control tumour volume (mm3 ± s.d.) 21 days after inoculation. CUnpaired t test. dTwo toxic
deaths before day 21.48 R. BRADFORD et al.
regression in two ofthe eight tumours. At day 21 the ratio TIC
was 0.7 but the differences in mean tumour volume between the
treated and the control group did not reach statistical
significance. The mean growth dealy at this dose was 1.4 days.
Subcutaneous 497-P(I) tumours also showed minimal response
when the dose of PCB was increased to 200 mg kg-'. The
difference in mean tumour volume between treated and control
groups did reach statistical significance (P = 0.002), but the
ratio TIC was only 0.69 and the GD 0.3 days. There were no
toxic deaths in the non-tumour-bearing drugcontrols. PCB in a
dose of 300 mg kg-' produced one toxic death in the drug
control group. Two tumour-bearing animals also died on day
18,4daysaftertheend ofthe treatment. Since nountreated mice
bearing subcutaneous tumours had died as a direct result of
their tumour burden these two deaths were also attributed to
drug toxicity. Four tumours were therefore lost to volume
assessment atday 21. Response to PCB at adoseof300 mg kg-'
remained negligible with no tumour regressions, a ratio TIC of
0.67 and a GD of 0.7 days.
Chemotherapy ofintracerebral tumours
The results are summarised in Table II and III.
BCNU Administration of BCNU as a single dose of
30 mg kg-' increased the median survival of tumour-bearing
animals to 18 days in experiment 1 and to 17 days in
experiment 2 compared to control values of 12.5 and 12 days
respectively. This represents survival increases of 144% and
141% and gives a mean life-span of 142.5%. BCNU was also
effective in prolonging survival when the total dose of
30 mg kg- ' was given as five consecutive divided doses begin-
ning on day 6. The mean life-span obtained from the two
experiments was 135.5%. All increases in survival were statis-
tically significant.
CCNU This drug was also capable of producing
significantly prolonged survival in mice bearing intracerebral
tumours. A single dose of 30 mg kg-' increased median sur-
vival to 17 days in experiment I and 15.5 days in experiment
2 compared to the same control values given above for these
experiments. Five divided doses of 6 mg kg-' increased
median survival to 16 days in experiment I and 17 days in
experiment 3 compared to control values of 12.5 and 13 days
respectively. The mean life-spans were 132.5% and 129.5%
for the single and multiple dose schedules respectively. In
agreement with the results obtained from the subcutaneous
model, the effect of CCNU in equivalent doses and schedules
was less than the effect of BCNU.
VCR VCR was administered as five consecutive doses of
270 fg kg-' beginning on day 6. Somewhat greater variability
occurred with VCR than with the other agents tested. In
experiment I median survival was increased to 16 days com-
pared to the control value of 12.5 days. This represents a
survival increase of 128%. In experiment 2, however, the
median survival of treated animals was only 14 days com-
pared to the control value of 13 days, giving an ILS of
108%.
PCB The median survival for both the treated groups was
13.5 days compared to control values of 12.5 days in experi-
ment 1 and 13 days in experiment 4. These represent survival
increases of only 108% and 104%. Neither of these increases
was statistically significant.
In these experiments there were no long-term survivors
among either the untreated control animals or the 120
animals that made up the various treatment groups.
Discussion
One of the criteria for an animal model of human glioma is
that it should correlate with the therapeutic sensitivities of
human malignant gliomas. The experiments described in this
paper have documented the effect of BCNU, CCNU, VCR
and PCB aganst the subcutaneous and intracerebral VM
model.
Although the use of tumours growing in extracerebral sites
has been subject to much criticism, there has been renewed
interest in the use of the subcutaneous model (Shapiro &
Basler, 1979; Schold & Bigner, 1983). While intracerebral
tumour models more closely resemble human brain tumours
a subcutaneous model allows in vivo cellular sensitivity to be
separated from any problems of drug delivery and the role of
the blood-brain barrier and permits the rapid accumulation
of serial quantitative data. In the present study the nitro-
soureas BCNU and CCNU produced the greatest effect on
subcutaneous tumours. VCR produced significant volume
reduction at day 21, 7 days after the end of treatment, but
did not produce consistent volume reduction with only four
of nine tumours regressing. Growth delay produced by VCR
was also modest. The variable response to VCR observed
with this model is of interest. The greatest variability in in
vitro chemosensitivity of the cloned cell lines derived from
VMDk P497 (Koppel et al., 1987) was to the vinca alkaloids
VCR and vindesine (Bradford et al., 1987). The variability in
response to VCR may reflect the different proportions of
sensitive and resistant clonal subpopulations in 497-P(1)
Table II Effect of BCNU and CCNU against intracerebral 497-P(1)
Median day ofdeath Signiyicance' Mean life
Group' Experiment (TIC) (P) %ILS span (%)
BCNU 1 18/12.5 0.002 144
30mg kg-' x 1 2 17/12 0.0003 141 142.5
BCNU 1 17.5/12.5 0.0005 140
6mgkg-] x 5 3 17/13 0.0001 131 135.5
CCNU 1 17/12.5 0.0005 136
30mgkg' x 1 2 15.5/12 0.0003 129 132.5
CCNU 1 16/12.5 0.006 128
6 mg kg-' x 5 3 17/13 0.0002 131 129.5
'Control and experimental groups consisted of 10 animals each. bWilcoxon rank sum test.
Table III Effect of VCR and PCB against intracerebral 497-P(1)
Median day ofdeath Significance' Mean life
Groupa Experiment (TIC) (P) %ILS span (%)
VCR 1 16/12.5 0.0005 128
270jgkg-'x 5 4 14/13 0.02 108 118
PCB
100mgkg' x 5 1 13.5/12.5 0.052 108
200mgkg' x 5 4 13.5/13 0.44 104 -
aControl and experimental groups consisted of 10 animals each. bWilcoxon rank sum test.CHEMOTHERAPY OF MURINE GLIOMA 49
tumours. Variations in the proportions of VCR sensitive and
resistant subpopulations may also influence the rapidity with
which resistance to VCR can develop. It has been shown that
this occurred rapidly when P497 intracerebral tumours were
treated with VCR (Bradford et al., 1987).
PCB was ineffective at any dosage level. It is unlikely that
the failure of response to PCB is due to inadequate dosage
levels since some systemic toxicity did occur at the highest
dose. It is more likely that there is inherent resistance of
497-P(1) cells to PCB, as has been seen in in vitro studies
(Bradford et al., 1987, 1988a).
The major emphasis of experimental chemotherapy of in-
tracranial tumours has been on the effect of agents on pro-
longation of animal survival. Bigner and Swenberg (1979)
have stated that ideally in an animal model of human glioma
there should be significant increases in survival following
treatment with the nitrosoureas. In the doses and schedules
used in this study both BCNU and CCNU produced a
significant extension of life, BCNU being marginally superior
to CCNU. This demonstrates that clinically useful drugs are
selected by the system. The optimal increases in ILS of
142.5% for BCNU and 132.5% for CCNU are, however,
modest when compared to the results obtained with other
animal models. In contrast to studies with the ependymoblas-
toma model (reviewed by Shapiro, 1974) no 'cures' were
obtained. The most effective drug tested was CCNU. Single
doses of between 30 and 50 mg kg-' regularly produced
80-90% cures when given on day 2 and a somewhat lower
cure rate when given on days 7 and 14 following inoculation.
BCNU was found to be less effective than CCNU, producing
cures of 30-40% in the same kinds of schedules (Shapiro et
al., 1970). In the large study of Geran et al. (1974) BCNU
produced 78% long-term survivors. It is important to note
that these drugs very rarely produce cures in man.
A tumour model which is particularly chemosensitive, like
the ependymoblastoma A (Geran et al., 1974) and glioma 26
(Levin et al., 1976), is likely to overpredict the activity of
some agents. The increase in survival of 497-P(1) tumour-
bearing mice produced by BCNU and CCNU is similar to
that observed in the avian sarcoma virus induced glioma
(Bigner et al., 1975). The results from both these models
closely parallel reports of nitrosourea treatment of human
gliomas. Animal survival studies using the 9L model have
shown that single LD1O doses of BCNU are at least as
effective as up to one and a half times that amount given as
divided doses (Rosenblum et al., 1983). In the studies pres-
ented here, both BCNU and CCNU given as a single dose
were marginally more effective in prolonging the life-span of
VM mice than the equivalent given as five divided doses.
Similar findings were also made by Geran et al. (1974).
Rosenblum et al. (1983), using the 9L system and clonogenic
cell survival studies, found that the administration of single
large doses of BCNU resulted in the larger tumour cell kill,
longer proliferation lag and slower repopulation rate than
with smaller split doses. These data suggest that human
treatment protocols should show greatest efficacy from the
nitrosoureas when single large doses rather than fractionated
schedules are used. A more recent study (Mbidde et al., 1988)
has shown a small prolongation of survival, but no increase
in the proportion of long-term survivors in patients with
recurrent malignant glioma who were treated with high dose
BCNU and autologous bone marrow rescue.
It is disappointing that this model does not respond to
PCB, particularly in the light of its activity against human
malignant glioma. Wilson (1978) has suggested that the
failure of some animal models to respond to PCB may reflect
differences in the metabolism of the drug between rodents
and humans. This may be true for the rat but is unlikely to
be so for the mouse because of the dramatic results obtained
with PCB in other murine models (Geran et al., 1974; Schold
et al., 1983). Both in vitro and in vivo in this model of glioma
PCB has consistently been the least effective agent used. This
is probably due to the inherent cellular resistance of cell line
497-P(l) to PCB.
To date the VM glioma model has largely been used to
confirm data already available from other animal models and
from clinical studies. Its role in the future will be to predict
the clinical efficacy of new therapies. It is currently being
used to evaluate the effect of compounds for photodynamic
therapy (Sandeman et al., 1987) and to screen a number of
recently synthesised cytotoxic compounds.
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